Urinary Incontinence Clinical Trial
— SOUNDSOfficial title:
Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS):an Observational Study
NCT number | NCT02186041 |
Other study ID # | 1.05.7008 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 2014 |
Est. completion date | March 22, 2021 |
Verified date | July 2021 |
Source | MedtronicNeuro |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to document the safety, the effectiveness, the continued performance at mid and long term, the morbidity and the percent of surgical revisions of the Interstim® therapy for up to 5 years in a representative sample of French centers under real-life conditions of use.
Status | Completed |
Enrollment | 320 |
Est. completion date | March 22, 2021 |
Est. primary completion date | March 22, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient is at least 18 years old; - Patient signed the Patient Data Release Form; - Patient suffering from retention or Over Active Bladder; - Patient is eligible for Interstim® system therapy. Exclusion Criteria: - Difficulty of collecting follow up patient data; - Patient not affiliated to social security. |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier du Pays d'Aix | Aix en Provence | |
France | CHIC Alencon Mamers | Alencon | |
France | CHU Angers | Angers | |
France | Hopital Prive Sevigné | Cesson Sevigné | |
France | Clinique Chirurgicale du Pre | Le Mans | |
France | CHRU Lille | Lille | |
France | Clinique Mutualiste de la porte de l'Orient | Lorient | |
France | Clinique Mutualiste de la Porte de lOrient | Lorient | |
France | APHM Hôpital Nord | Marseille | |
France | APM Hopital de La Conception | Marseille | |
France | Hopital Robert Schuman | Metz | |
France | CHU de Nantes - Hôtel Dieu | Nantes | |
France | Groupe Hospitalier Diaconesses Croix Saint-Simon | Paris | |
France | CHU Bordeaux - Centre Universitaire Pellegrin | Pessac | |
France | Maison des consultations - Centre Briochin d'Urologie | Plerin | |
France | Groupe Courlancy | Reims | |
France | CH Roubaix | Roubaix | |
France | CHU Rouen - Hopital Charles Nicolle | Rouen | |
France | Clinique Urologique Nantes Atlantis | Saint Herblain | |
France | CH Sarreguemines | Sarreguemines | |
France | Hopital Civil Strasbourg | Strasbourg | |
France | Polyclinique Ormeau | Tarbes | |
France | CHU Toulouse - Hopital Rangueil | Toulouse | |
France | Clinique Ambroise Pare | Toulouse |
Lead Sponsor | Collaborator |
---|---|
MedtronicNeuro | Medtronic France SAS |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and Performance (2 years) - Objective #1 | To evaluate the safety of Interstim® therapy and the performance of the Interstim® system in the 2 years following the enrollment.
The rate of surgical revisions/explantations of the Interstim® system or any of its parts will be measured. |
24 months | |
Secondary | Safety and Performance (5 years) - Objective #2 | To evaluate the safety of Interstim® therapy and the performance of the Interstim® system in the 5 years following the enrollment.
The rate of adverse device events and device deficiencies will be measured. |
5 years | |
Secondary | Concomitant treatment - Objective #3 | To evaluate the use of concomitant treatments or interventions dedicated to intractable urinary voiding dysfunctions. | Up to 5 years | |
Secondary | NRS evaluation - Objective#4 | To evaluate the effect of InterStim® therapy on the perceived bother resulting from conditions as measured on Numeric Rating Scale (NRS) up to 5 years follow up. | Up to 5 years | |
Secondary | Effect of Therapy in UR patients - Objective #5 | To assess the effect of Interstim® therapy on the subset of patients with urinary retention as measured by the number of self-catheterizations per day. | Up to 5 years | |
Secondary | Effect of therapy on OAB patients - Objective#6 | To assess the effect of Interstim® therapy on the subset of patients with Over Active Bladder (OAB wet and OAB dry) symptom as measured by the number of voids and leaks per day. | Up to 5 years | |
Secondary | Quality of Life (DITROVIE) - Objective#7 | To assess the therapy effect on Quality of Life using the DITROVIE questionnaire. | Up to 5 years | |
Secondary | Quality of Life (EQ-5D-5L) - Objective#8 | To assess the therapy effect on Quality of Life using the EQ-5D-5L questionnaire. | Up to 5 years | |
Secondary | Urinary symptoms (USP) - Objective#9 | To evaluate the change of urinary symptoms of all patients implanted with Interstim® using the Urinary Symptom Profile (USP) questionnaire. | Up to 5 years | |
Secondary | Goal attainment assessment - Objective#10 | To evaluate the long term goal attainment assessed by the GAS. | Up to 5 years | |
Secondary | Assessment of Fecal Incontinence - Objective#11 | To assess the therapy effect on fecal incontinence for subset of patients with double incontinence using the WEXNER fecal incontinence score. | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05534412 -
A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence
|
N/A | |
Recruiting |
NCT05515198 -
Improving Care for Women With Urinary Incontinence (EMPOWER)
|
N/A | |
Completed |
NCT04071301 -
Collection of Real-life Measurement Data for TENA SmartCare Change Indicator in Subjects With Urinary Incontinence
|
N/A | |
Completed |
NCT03623880 -
Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders
|
N/A | |
Recruiting |
NCT05880862 -
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
|
Early Phase 1 | |
Recruiting |
NCT04159467 -
Effect of Pelvic Floor Muscle Training on Urinary Incontinence Reports in Obese Women Undergoing a Low Calorie Diet
|
N/A | |
Completed |
NCT05485922 -
Performance of a Single-use Intermittent Micro-hole Zone Catheter
|
N/A | |
Completed |
NCT06268782 -
The Effectiveness of an Online Exercise Program on Well-being of Postpartum Women
|
N/A | |
Not yet recruiting |
NCT03027986 -
Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy
|
N/A | |
Recruiting |
NCT02490917 -
ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence
|
N/A | |
Enrolling by invitation |
NCT02530372 -
Feasibility of the UriCap-F for Urine Collection in Hospitalized Women
|
N/A | |
Enrolling by invitation |
NCT02529371 -
Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients
|
N/A | |
Completed |
NCT02338726 -
Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study
|
N/A | |
Completed |
NCT02600676 -
Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis
|
N/A | |
Completed |
NCT02549729 -
Effect of the Pelvic Floor Training in Postmenopausal Women With or Without Hormonal Therapy
|
N/A | |
Completed |
NCT02368262 -
Prevalence of Incontinence and Risk Factors in Children With Cerebral Palsy
|
N/A | |
Completed |
NCT02239796 -
Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence
|
N/A | |
Completed |
NCT01942681 -
Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride
|
N/A | |
Recruiting |
NCT01804153 -
Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO)
|
Phase 1/Phase 2 | |
Completed |
NCT01520948 -
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
|
Phase 3 |